NCT07175077 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
| NCT ID | NCT07175077 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Missouri-Columbia |
| Condition | Small-cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-11-01 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Comparison of a 7t MRI to standard of care 1.5t/3t MRI scans to determine if earlier detection of brain metastases are possible on a 7t.
Eligibility Criteria
Inclusion Criteria: * Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC). • Patient must have an MRI of the brain, performed within 4 weeks prior to consent, documenting no evidence of brain metastases or leptomeningeal disease. * Patient also must not have a history of brain metastases or leptomeningeal disease. * Patient must refuse PCI and agree to surveillance with brain MRI scans (1.5T/3T). * Patient must be ≥ 18 years of age. * Patient must have ECOG Performance Status of 0-2 * Patients must be able to tolerate the 7T MRI Exclusion Criteria: * Patient must not have a contraindication to an MRI, such as implanted metal devices or foreign bodies. * Patient must not have a contraindication to gadolinium contrast administration during MR imaging. * Patient must not have other metastatic malignancies requiring current active treatment. * Pregnant patients are excluded. Pregnancy status will be confirmed verbally.
Contact & Investigator
Bo Lu, MD
PRINCIPAL INVESTIGATOR
CHAIR & PROFESSOR, DEPARTMENT OF RADIATION ONCOLOGY
Frequently Asked Questions
Who can join the NCT07175077 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Small-cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07175077 currently recruiting?
Yes, NCT07175077 is actively recruiting participants. Contact the research team at mcdanielbl@health.missouri.edu for enrollment information.
Where is the NCT07175077 trial being conducted?
This trial is being conducted at Columbia, United States.
Who is sponsoring the NCT07175077 clinical trial?
NCT07175077 is sponsored by University of Missouri-Columbia. The principal investigator is Bo Lu, MD at CHAIR & PROFESSOR, DEPARTMENT OF RADIATION ONCOLOGY. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.